Related Experiment Video
Updated: Sep 18, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Chronic Treatment with Angiotensin-(1-7) Improves Metabolism by Modulating Adipose Tissue and Oxidative Stress in
Alanna Fernandes Paraíso1, Jaciara Neves Sousa1, João Marcus Oliveira Andrade1
1Postgraduate Program in Health Science, Universidade Estadual de Montes Claros (Unimontes), Montes Claros, Minas Gerais, Brazil.
Background:
Angiotensin-(1-7) is a crucial endocrine modulatory peptide that can enhance conditions like diabetes, obesity, and other features of metabolic syndrome. However, there is a lack of data on its long-term effects.
Aim:
This study aimed to assess the impact of chronic oral administration of Angiotensin-( 1-7) on adipose tissue modulation and metabolic processes in mice.
Methods:
The Angiotensin-(1-7) peptide oral formulation was encapsulated within the hydroxypropyl-β-cyclodextrin oligosaccharide (HPβCD) matrix. Male Swiss mice were divided into 4 groups: standard diet (ST)+HPßCD; ST+Ang-(1-7); high-fat diet HFD+HPßCD, and HFD+Ang-(1-7). The treatment lasted for 12 months, during which body weight, food intake, glycemic and lipid profiles, visceral adiposity, oxidative stress indicators, histological parameters, quantitative real-time PCR assessments, and comprehensive in silico bioinformatics analyses were conducted.
Results:
Prolonged treatment with Ang-(1-7) led to improvements in glucose levels, visceral body adiposity, decreased cholesterol and triglyceride levels, and reduced oxidative stress. Bioinformatics analysis revealed that AKT1, an insulin signaling effector (INS), and key inflammatory markers like IL-6 and VEGF may be potential molecular mediators of Angiotensin-(1-7) effects. Non-obese animals treated with Angiotensin-(1- 7) showed increased expression levels of AKT1, supporting the findings from the bioinformatics analysis.
Conclusion:
This study demonstrates that chronic oral use of Ang-(1-7) enhances adipose and metabolic parameters, suggesting its potential as a long-term therapeutic agent for regulating metabolic disorders.
Insights
Chronic oral Angiotensin-(1-7) administration improved metabolic health in mice by reducing visceral adiposity and oxidative stress. This peptide shows potential as a long-term therapeutic for metabolic syndrome.
Area of Science:
- Endocrinology
- Metabolic Science
- Pharmacology
Background:
- Angiotensin-(1-7) is a key peptide hormone involved in metabolic regulation.
- Existing data on the long-term effects of Angiotensin-(1-7) is limited.
- Metabolic syndrome encompasses conditions like diabetes and obesity, often linked to endocrine dysfunction.
Purpose of the Study:
- To evaluate the long-term impact of orally administered Angiotensin-(1-7) on adipose tissue and metabolic processes.
- To assess the therapeutic potential of Angiotensin-(1-7) in a mouse model of metabolic dysfunction.
- To investigate the molecular mechanisms underlying Angiotensin-(1-7) action in metabolic regulation.
Main Methods:
- Oral Angiotensin-(1-7) was encapsulated in hydroxypropyl-β-cyclodextrin (HPβCD) for stability.
- Male Swiss mice were assigned to standard or high-fat diets, with or without Angiotensin-(1-7) treatment for 12 months.
- Comprehensive analyses included metabolic profiling, visceral adiposity assessment, oxidative stress markers, histology, qPCR, and in silico bioinformatics.
Main Results:
- Chronic Angiotensin-(1-7) treatment significantly improved glucose levels, reduced visceral adiposity, and lowered cholesterol and triglyceride levels.
- The peptide treatment also decreased markers of oxidative stress.
- Bioinformatics identified AKT1, INS, IL-6, and VEGF as potential mediators, with increased AKT1 expression observed in treated non-obese mice.
Conclusions:
- Long-term oral Angiotensin-(1-7) administration effectively modulates adipose tissue and improves metabolic parameters.
- These findings highlight Angiotensin-(1-7)'s potential as a therapeutic agent for managing metabolic disorders.
- Further research into Angiotensin-(1-7) could lead to novel treatments for obesity and diabetes.
